Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

NCT ID: NCT00742027

Last Updated: 2021-07-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 129 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-09-16
• Study Completion Date: 2013-08-12

Brief Summary

This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant. Safety of panobinostat also was assessed. Other markers that may correlate with efficacy or safety were explored.

Conditions

Classical Hodgkin's Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Panobinostat

Participants received panobinostat 40 mg, capsules, orally, thrice every week (i.e. days 1, 3 and 5), in each cycle of 21 days until unacceptable toxicity, disease progression, start of new anti-cancer therapy or withdrawal of consent (up to approximately 48 months).

Group Type: EXPERIMENTAL

Panobinostat

Intervention Type: DRUG

Panobinostat hard gelatin capsules.

Interventions

Panobinostat

Panobinostat hard gelatin capsules.

Intervention Type: DRUG

Other Intervention Names

LBH589; LBH

Eligibility Criteria

Inclusion Criteria

1. Participant age is ≥ 18 years.

2. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.

3. Participant has a history of classical Hodgkin's Lymphoma (HL) (i.e. Nodular sclerosing, Mixed-cellularity, Lymphocyte-rich, Lymphocyte depleted).

4. Participant has progressive disease after receiving high dose chemotherapy with autologous hematopoietic stem cell transplant (AHSCT).

Note: If last therapy was ≥ 18 months ago, then biopsy should be performed to confirm diagnosis.

Note: Participant should have received ≤ 5 prior systemic treatment regimens (See Post-text supplement 2 for definitions and examples).

Note: Participant will be allowed on study who have also received an allogeneic hematopoietic stem cell transplant, however this therapy alone is not sufficient for inclusion into this study.

5. Participant has at least one site of measurable nodal disease at baseline ≥ 2.0 centimeter (cm) in the longest transverse diameter and clearly measurable in at least two perpendicular dimensions, as determined by computed tomography (CT) scan (magnetic resonance imaging [MRI] is allowed only if CT scan can not be performed).

Note: Participant with bone marrow involvement are eligible, but this criteria alone should not be used for disease measurement.

6. Participant has the following laboratory values (labs may be repeated, if needed, to obtain acceptable values before screen fail):

• Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/liter (L) [International System of Units {SI} units 1.5 x 10^9/L].
• Platelet count ≥ 75 x 10^9/L.
• Serum potassium, magnesium, phosphorus, sodium, total calcium (corrected for serum albumin) or ionized calcium within normal limits (WNL) for the institution.

Note: Potassium, calcium, magnesium, sodium, and/or phosphorus supplements may be given to correct values that are < lower limits of normal (LLN). Post-correction values must not be deemed to be a clinically significant abnormality prior to participant being dosed.

• Serum creatinine ≤ 1.5 x upper limits of normal (ULN).
• Serum bilirubin ≤ 1.5 x ULN (or ≤ 3.0 x ULN, if participant has Gilbert syndrome).
• Aspartate transaminase (AST)/ serum glutamic oxaloacetic transaminase (SGOT) and/or alanine transaminase (ALT)/ serum glutamic pyruvic transaminase (SGPT) ≤ 2.5 x ULN or ≤ 5.0 x ULN if the transaminase elevation is due to disease involvement.

7. Clinically euthyroid. Note: Participants are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism.

8. Written informed consent was obtained from the participant prior to any study-specific screening procedures.

9. Participant has the ability to swallow capsules or tablets.

Exclusion Criteria

1. Participant has a history of prior treatment with a deacetylase (DAC) inhibitor including panobinostat.

2. Participant will need valproic acid for any medical condition during the study or within 5 days prior to the first panobinostat treatment.

3. Participant has been treated with monoclonal antibody therapy (e.g., rituximab or anti CD-30 antibody, etc.) within 4 weeks of start of study treatment.

4. Participant has received chemotherapy or any investigational drug or undergone major surgery ≤ 2 weeks prior to starting study drug or whose side effects of such therapy have not resolved to ≤ grade 1.

5. Participant has been treated with > 5 prior systemic lines of treatment (see Post-text supplement 2 for definitions and examples).

6. Participant has received prior radiation therapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks prior to start of study treatment or whose side effects of such therapy have not resolved to ≤ grade 1.

7. Participant is using any anti-cancer therapy concomitantly.

8. Participant treated with allogeneic hematopoietic stem cell transplant who is currently on or has received immunosuppressive therapy within 90 days prior to start of screening and/or have ≥ Grade 2 graft versus host disease (GvHD).

9. Participant has a history of another primary malignancy ≤ 3 years before study entry, with the exception of non-melanoma skin cancer, and carcinoma in situ of uterine cervix.

10. Participant has a history of central nervous system (CNS) involvement with lymphoma.

11. Participant has impaired cardiac function including any of the following:

• Complete left bundle branch block or use of a permanent cardiac pacemaker, congenital long QT syndrome, history or presence of ventricular tachyarrhythmias, clinically significant resting bradycardia (<50 beats per minute [bpm]), QT interval (QTcF) > 450 milliseconds (msec) on screening electrocardiography (ECG), or right bundle branch block + left anterior hemiblock (bifascicular block).
• Presence of atrial fibrillation (ventricular heart rate >100 bpm).
• Previous history angina pectoris or acute myocardial infarction (MI) within 6 months.
• Congestive heart failure (New York Heart Association functional classification III-IV) or baseline multigated acquisition (MUGA)/Echo shows left ventricular ejection fraction (LVEF) < 45%.

12. Participant has any other clinically significant heart disease (e.g., uncontrolled hypertension).

13. Participant has an impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, obstruction, or stomach and/or small bowel resection).

14. Participant has unresolved diarrhea ≥ grade 2.

15. Participant has any other concurrent severe and/or uncontrolled medical condition(s) (e.g., uncontrolled diabetes mellitus, active or uncontrolled infection, chronic obstructive or chronic restrictive pulmonary disease including dyspnoea at rest from any cause) that could cause unacceptable safety risks or compromise compliance with the protocol.

16. Participant has a known history of human immunodeficiency virus (HIV) seropositivity (screening HIV testing is not required).

17. Participant is using medications that have a relative risk of prolonging the QT interval or of inducing Torsade de Pointes, where such treatment cannot be discontinued or switched to a different medication prior to starting study drug.

18. Participant is a woman who is pregnant or breast feeding, or a women of childbearing potential (WOCBP) not willing to use a double method of contraception during the study through 3 months after the end of treatment. One of these methods of contraception must be a barrier method. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). WOCBP must have a negative serum pregnancy test at baseline.

19. Male participant whose sexual partner(s) are WOCBP who are not willing to use a double method of contraception, one of which includes a condom, during the study and for 3 months after the end of treatment.

Participants with any of the following contraindications to positron emission tomography (PET) are excluded from the [18F]- fludeoxyglucose (FDG) PET study (only applicable for centers participating in the PET study):

20. Fasting blood glucose above 200 milligrams per deciliter (mg/dL), at time of PET scan.

21. Inability to lay down for 60 minutes or has a history of claustrophobia.

22. Participant not at a participating center.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(2)

Duarte, California, United States

Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2)

Atlanta, Georgia, United States

Georgia Regents University Cancer Clinical Research Unit

Augusta, Georgia, United States

Rush University Medical Center Divisionof Hem/Onc Research(2)

Chicago, Illinois, United States

VA Maryland Health Care Dept.of GreenbaumCancerCent(5)

Baltimore, Maryland, United States

Dana Farber Cancer Institute Hematology / Oncology

Boston, Massachusetts, United States

Karmanos Cancer Institute Div.of Hematology/Oncology

Detroit, Michigan, United States

Mayo Clinic - Rochester Hematology

Rochester, Minnesota, United States

University of Pennsylvania Medical Center Dept of UPenn Med Ctr (3)

Philadelphia, Pennsylvania, United States

University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3)

Houston, Texas, United States

The Methodist Hospital Cell & Gene Therapy Clinic

Houston, Texas, United States

Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5)

San Antonio, Texas, United States

West Virginia University/ Mary Babb Randolph Cancer Center

Morgantown, West Virginia, United States

Novartis Investigative Site

Herston, Queensland, Australia

Novartis Investigative Site

Malvern, Victoria, Australia

Novartis Investigative Site

Brussels, , Belgium

Novartis Investigative Site

Charleroi, , Belgium

Novartis Investigative Site

Leuven, , Belgium

Novartis Investigative Site

Rio de Janeiro, Rio de Janeiro, Brazil

Novartis Investigative Site

Campinas, São Paulo, Brazil

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Novartis Investigative Site

Dijon, , France

Novartis Investigative Site

Lille, , France

Novartis Investigative Site

Lyon, , France

Novartis Investigative Site

Marseille, , France

Novartis Investigative Site

Rennes, , France

Novartis Investigative Site

Villejuif, , France

Novartis Investigative Site

Cologne, , Germany

Novartis Investigative Site

Dresden, , Germany

Novartis Investigative Site

Göttingen, , Germany

Novartis Investigative Site

Beersheba, , Israel

Novartis Investigative Site

Jerusalem, , Israel

Novartis Investigative Site

Ramat Gan, , Israel

Novartis Investigative Site

Bologna, BO, Italy

Novartis Investigative Site

Milan, MI, Italy

Novartis Investigative Site

Rozzano, MI, Italy

Novartis Investigative Site

Torino, TO, Italy

Novartis Investigative Site

Udine, UD, Italy

Novartis Investigative Site

Kuala Selangor, , Malaysia

Novartis Investigative Site

Auckland, , New Zealand

Novartis Investigative Site

Singapore, , Singapore

Novartis Investigative Site

Barcelona, Catalonia, Spain

Novartis Investigative Site

Madrid, , Spain

Novartis Investigative Site

Withington, Greater Manchester, United Kingdom

Novartis Investigative Site

Southampton, , United Kingdom

Countries

United States; Australia; Belgium; Brazil; France; Germany; Israel; Italy; Malaysia; New Zealand; Singapore; Spain; United Kingdom

References

Chari A, Cho HJ, Dhadwal A, Morgan G, La L, Zarychta K, Catamero D, Florendo E, Stevens N, Verina D, Chan E, Leshchenko V, Lagana A, Perumal D, Mei AH, Tung K, Fukui J, Jagannath S, Parekh S. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 2017 Aug 21;1(19):1575-1583. doi: 10.1182/bloodadvances.2017007427. eCollection 2017 Aug 22.

Reference Type: DERIVED

PMID: 29296798 (View on PubMed)

Harrison SJ, Hsu AK, Neeson P, Younes A, Sureda A, Engert A, Prince HM, Li M, Savage P, Bugarini R, Williams D, Squier M, Ritchie DS. Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leuk Lymphoma. 2014 May;55(5):1053-60. doi: 10.3109/10428194.2013.820287. Epub 2013 Aug 5.

Reference Type: DERIVED

PMID: 23822537 (View on PubMed)

Other Identifiers

2008-003016-35

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CLBH589E2214

Identifier Type: -

Identifier Source: org_study_id